Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.72 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941203 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL2092567 | 0.85 | KDM4E (0.71) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL17962428 | 0.85 | KDM4E (0.72) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL9417737 | 0.84 | SIGMAR1 (0.72) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL3968896 | 0.84 | KDM4E (0.70) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL18753626 | 0.84 | KDM4E (0.70) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL2094238 | 0.84 | KDM4E (0.70) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL4105461 | 0.84 | CYP2A13 (1.00) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| Hydrochloric Acid SCHEMBL11467058 | 0.82 | SIGMAR1 (0.70) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 | |
| SCHEMBL3210628 | 0.82 | ALDH1A1 (0.73) | ALDH1A1KDM4EPOLBCYP2A13CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951660-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8389743-B2 | Histamine-3 receptor antagonists | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | PFIZER INC. | 2012-08-30 | — | — | US | disclosed |
| US-8158673-B2 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1951660-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC | 2008-04-24 | — | — | US | disclosed |
| WO-2007049123-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | HRH3, HRH4, HRH2 | ALDH1A1 1257/4885KDM4E 3423/4885POLB 1544/4885 |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | HRH3, HRH4, HRH1 | ALDH1A1 1965/4885KDM4E 3022/4885POLB 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.